Trial Profile

A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin vs Switching to Rosuvastatin or Doubling the Statin Dose

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
Indications Cardiovascular disorders; Hyperlipidaemia
Focus Therapeutic Use
Acronyms COMPLETED
Sponsors Merck Sharp & Dohme; Organon

16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
25 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
25 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com